MD, FCRP, Leopold G. Koss,
Leopold G. Koss, MD, FCRP,
MD, FIAC, Rana S. Hoda,
Rana S. Hoda, MD, FIAC
e.a.
Springer New York
e druk, 2016
9781493952755
Koss's Cytology of the Urinary Tract with Histopathologic Correlations
Specificaties
Paperback, blz.
|
Engels
Springer New York |
e druk, 2016
ISBN13: 9781493952755
Rubricering
Verwachte levertijd ongeveer 9 werkdagen
Samenvatting
This new volume fills the gap in the literature as it will guide urologists and pathologists in the proper utilization of a variety of laboratory methods that are currently available to determine the presence, persistence or progression of tumors of the lower urinary tract. The volume emphasizes cytology of the urinary tract which is preferred over other methods (i.e. biochemical, immunological and cytogenetic) for its accuracy, especially for the important high grade tumors. This volume will appeal to urologists as well as pathologists, cytopathologists and related professions. The illustrations, nearly all in color, stress the key points of the text and enhance basic understanding of urothelial and other tumors of the urinary tract.
Specificaties
ISBN13:9781493952755
Taal:Engels
Bindwijze:paperback
Uitgever:Springer New York
Inhoudsopgave
<p>Chapter 1- Introduction</p><p>Chapter 2- Indication, Collection and Laboratory Processing of Cytologic Samples</p><p>Principal Indication</p><p>Collection Techniques</p><p>Laboratory Processing of Samples</p><p>Suggested Reading</p><p>Chapter 3- The Cellular and Acellular Components of the Urinary Sediment</p><p>Normal Urothelium (Transitional Epithelium) and Its Cells</p><p>Other Benign Cells</p><p>Noncellular Components of the Urinary Sediment</p><p>Suggested Reading <p>Chapter 4- The Cytologic Makeup of the Urinary Sediment According to the Collection Technique</p><p>Voided urine</p><p>Cytologic Makeup of Bladder Washings </p><p>Cytologic Makeup of Normal Specimens Obtained by Retrograde Catheterization </p><p>Cytologic Makeup of Smears Obtained by Brushing</p><p>Cytologic Makeup of Ileal Bladder Urine</p><p><br></p><p>Chapter 5- Cytologic Manifestations of Benign Disorders Affecting Cells of the</p><p>Lower Urinary Tract</p><p>Inflammatory disorders <p>Cellular inclusions not due to viral agents</p><p>Trematodes and other parasites</p><p>Lithiasis</p><p>Leukoplakia</p><p>Effect of Drugs</p><p>Effects of radiotherapy</p><p>Monitoring of renal transplant patients</p><p>Urinary Cytology in Renal Transplant Patients</p><p>Rare benign conditions</p><p>Suggested Reading</p><p>Chapter 6- Tumors of the Bladder</p><p>Non-Neoplastic Changes</p><p>Hyperplasia</p><p>Inverted papilloma</p><p>Urothelial (Transitional) Cell Tumors </p><p>Epidemiology</p><p>Classification and natural history</p><p>Types of Urothelial Tumors</p><p><p>A. Papillary Urothelial Neoplasms</p><p></p><p>I. Tumors with No/Minimal Nuclear Atypia </p><p>Papilloma, PUNLMP, low grade Papillary Urothelial Carcinoma </p><p><p>II. High-Grade Papillary Urothelial Carcinoma</p><p><p>B. Nonpapillary Urothelial Tumors</p><p>I. Invasive Urothelial Carcinomas</p><p>II. Flat Carcinoma In Situ (IUN III): Clinical Presentation, Histology</p><p></p><p>Histologic Variants of Urothelial Carcinoma</p><p>Metastatic Tumors </p><p>Cytologic Monitoring of Patients Treated for Tumors of Lower Urinary Tract</p><p>Reporting of cytologic findings</p><p>Suggested Reading</p><p>Chapter 7- Immunohistochemistry, Immunocytochemistry and Other Methods of Detection of Bladder Neoplasms</p><p>Introduction</p><p>US FDA-approved Markers</p><p>Potential Markers in Earlier Phases of Clinical Development</p><p>Markers Detected by Immunocytochemistry</p><p>Comparison between Urine Cytology and FDA-approved Markers</p><p>Conclusion</p><p>References</p><p></p></p><p>Chapter 4- The Cytologic Makeup of the Urinary Sediment According to the Collection Technique</p><p>Voided urine</p><p>Cytologic Makeup of Bladder Washings </p><p>Cytologic Makeup of Normal Specimens Obtained by Retrograde Catheterization </p><p>Cytologic Makeup of Smears Obtained by Brushing</p><p>Cytologic Makeup of Ileal Bladder Urine</p><p><br></p><p>Chapter 5- Cytologic Manifestations of Benign Disorders Affecting Cells of the</p><p>Lower Urinary Tract</p><p>Inflammatory disorders <p>Cellular inclusions not due to viral agents</p><p>Trematodes and other parasites</p><p>Lithiasis</p><p>Leukoplakia</p><p>Effect of Drugs</p><p>Effects of radiotherapy</p><p>Monitoring of renal transplant patients</p><p>Urinary Cytology in Renal Transplant Patients</p><p>Rare benign conditions</p><p>Suggested Reading</p><p>Chapter 6- Tumors of the Bladder</p><p>Non-Neoplastic Changes</p><p>Hyperplasia</p><p>Inverted papilloma</p><p>Urothelial (Transitional) Cell Tumors </p><p>Epidemiology</p><p>Classification and natural history</p><p>Types of Urothelial Tumors</p><p><p>A. Papillary Urothelial Neoplasms</p><p></p><p>I. Tumors with No/Minimal Nuclear Atypia </p><p>Papilloma, PUNLMP, low grade Papillary Urothelial Carcinoma </p><p><p>II. High-Grade Papillary Urothelial Carcinoma</p><p><p>B. Nonpapillary Urothelial Tumors</p><p>I. Invasive Urothelial Carcinomas</p><p>II. Flat Carcinoma In Situ (IUN III): Clinical Presentation, Histology</p><p></p><p>Histologic Variants of Urothelial Carcinoma</p><p>Metastatic Tumors </p><p>Cytologic Monitoring of Patients Treated for Tumors of Lower Urinary Tract</p><p>Reporting of cytologic findings</p><p>Suggested Reading</p><p>Chapter 7- Immunohistochemistry, Immunocytochemistry and Other Methods of Detection of Bladder Neoplasms</p><p>Introduction</p><p>US FDA-approved Markers</p><p>Potential Markers in Earlier Phases of Clinical Development</p><p>Markers Detected by Immunocytochemistry</p><p>Comparison between Urine Cytology and FDA-approved Markers</p><p>Conclusion</p><p>References</p><p></p><p>Cellular inclusions not due to viral agents</p><p>Trematodes and other parasites</p><p>Lithiasis</p><p>Leukoplakia</p><p>Effect of Drugs</p><p>Effects of radiotherapy</p><p>Monitoring of renal transplant patients</p><p>Urinary Cytology in Renal Transplant Patients</p><p>Rare benign conditions</p><p>Suggested Reading</p><p>Chapter 6- Tumors of the Bladder</p><p>Non-Neoplastic Changes</p><p>Hyperplasia</p><p>Inverted papilloma</p><p>Urothelial (Transitional) Cell Tumors </p><p>Epidemiology</p><p>Classification and natural history</p><p>Types of Urothelial Tumors</p><p><p>A. Papillary Urothelial Neoplasms</p><p></p><p>I. Tumors with No/Minimal Nuclear Atypia </p><p>Papilloma, PUNLMP, low grade Papillary Urothelial Carcinoma </p><p><p>II. High-Grade Papillary Urothelial Carcinoma</p><p><p>B. Nonpapillary Urothelial Tumors</p><p>I. Invasive Urothelial Carcinomas</p><p>II. Flat Carcinoma In Situ (IUN III): Clinical Presentation, Histology</p><p></p><p>Histologic Variants of Urothelial Carcinoma</p><p>Metastatic Tumors </p><p>Cytologic Monitoring of Patients Treated for Tumors of Lower Urinary Tract</p><p>Reporting of cytologic findings</p><p>Suggested Reading</p><p>Chapter 7- Immunohistochemistry, Immunocytochemistry and Other Methods of Detection of Bladder Neoplasms</p><p>Introduction</p><p>US FDA-approved Markers</p><p>Potential Markers in Earlier Phases of Clinical Development</p><p>Markers Detected by Immunocytochemistry</p><p>Comparison between Urine Cytology and FDA-approved Markers</p><p>Conclusion</p><p>References</p><p><p><p>Chapter 4- The Cytologic Makeup of the Urinary Sediment According to the Collection Technique</p><p>Voided urine</p><p>Cytologic Makeup of Bladder Washings </p><p>Cytologic Makeup of Normal Specimens Obtained by Retrograde Catheterization </p><p>Cytologic Makeup of Smears Obtained by Brushing</p><p>Cytologic Makeup of Ileal Bladder Urine</p><p><br></p><p>Chapter 5- Cytologic Manifestations of Benign Disorders Affecting Cells of the</p><p>Lower Urinary Tract</p><p>Inflammatory disorders <p>Cellular inclusions not due to viral agents</p><p>Trematodes and other parasites</p><p>Lithiasis</p><p>Leukoplakia</p><p>Effect of Drugs</p><p>Effects of radiotherapy</p><p>Monitoring of renal transplant patients</p><p>Urinary Cytology in Renal Transplant Patients</p><p>Rare benign conditions</p><p>Suggested Reading</p><p>Chapter 6- Tumors of the Bladder</p><p>Non-Neoplastic Changes</p><p>Hyperplasia</p><p>Inverted papilloma</p><p>Urothelial (Transitional) Cell Tumors </p><p>Epidemiology</p><p>Classification and natural history</p><p>Types of Urothelial Tumors</p><p><p>A. Papillary Urothelial Neoplasms</p><p></p><p>I. Tumors with No/Minimal Nuclear Atypia </p><p>Papilloma, PUNLMP, low grade Papillary Urothelial Carcinoma </p><p><p>II. High-Grade Papillary Urothelial Carcinoma</p><p><p>B. Nonpapillary Urothelial Tumors</p><p>I. Invasive Urothelial Carcinomas</p><p>II. Flat Carcinoma In Situ (IUN III): Clinical Presentation, Histology</p><p></p><p>Histologic Variants of Urothelial Carcinoma<p>Metastatic Tumors </p><p>Cytologic Monitoring of Patients Treated for Tumors of Lower Urinary Tract</p><p>Reporting of cytologic findings</p><p>Suggested Reading</p><p>Chapter 7- Immunohistochemistry, Immunocytochemistry and Other Methods of Detection of Bladder Neoplasms</p><p>Introduction</p><p>US FDA-approved Markers</p><p>Potential Markers in Earlier Phases of Clinical Development</p><p>Markers Detected by Immunocytochemistry</p><p>Comparison between Urine Cytology and FDA-approved Markers</p><p>Conclusion</p><p>References</p><p></p><p>Cellular inclusions not due to viral agents</p><p>Trematodes and other parasites</p><p>Lithiasis</p><p>Leukoplakia</p><p>Effect of Drugs</p><p>Effects of radiotherapy</p><p>Monitoring of renal transplant patients</p><p>Urinary Cytology in Renal Transplant Patients</p><p>Rare benign conditions</p><p>Suggested Reading</p><p>Chapter 6- Tumors of the Bladder</p><p>Non-Neoplastic Changes</p><p>Hyperplasia</p><p>Inverted papilloma</p><p>Urothelial (Transitional) Cell Tumors </p><p>Epidemiology</p><p>Classification and natural history</p><p>Types of Urothelial Tumors</p><p><p>A. Papillary Urothelial Neoplasms</p><p></p><p>I. Tumors with No/Minimal Nuclear Atypia </p><p>Papilloma, PUNLMP, low grade Papillary Urothelial Carcinoma </p><p><p>II. High-Grade Papillary Urothelial Carcinoma</p><p><p>B. Nonpapillary Urothelial Tumors</p><p>I. Invasive Urothelial Carcinomas</p><p>II. Flat Carcinoma In Situ (IUN III): Clinical Presentation, Histology</p><p></p><p>Histologic Variants of Urothelial Carcinoma</p><p>Metastatic Tumors </p><p>Cytologic Monitoring of Patients Treated for Tumors of Lower Urinary Tract</p><p>Reporting of cytologic findings</p><p>Suggested Reading</p><p>Chapter 7- Immunohistochemistry, Immunocytochemistry and Other Methods of Detection of Bladder Neoplasms</p><p>Introduction</p><p>US FDA-approved Markers</p><p>Potential Markers in Earlier Phases of Clinical Development</p><p>Markers Detected by Immunocytochemistry</p><p>Comparison between Urine Cytology and FDA-approved Markers</p><p>Conclusion</p><p>References</p><p><p>Cellular inclusions not due to viral agents</p><p>Trematodes and other parasites</p><p>Lithiasis</p><p>Leukoplakia</p><p>Effect of Drugs</p><p>Effects of radiotherapy</p><p>Monitoring of renal transplant patients</p><p>Urinary Cytology in Renal Transplant Patients</p><p>Rare benign conditions</p><p>Suggested Reading</p><p>Chapter 6- Tumors of the Bladder</p><p>Non-Neoplastic Changes</p><p>Hyperplasia</p><p>Inverted papilloma</p><p>Urothelial (Transitional) Cell Tumors </p><p>Epidemiology</p><p>Classification and natural history</p><p>Types of Urothelial Tumors</p><p><p>A. Papillary Urothelial Neoplasms</p><p></p><p>I. Tumors with No/Minimal Nuclear Atypia </p><p>Papilloma, PUNLMP, low grade Papillary Urothelial Carcinoma </p><p><p>II. High-Grade Papillary Urothelial Carcinoma</p><p><p>B. Nonpapillary Urothelial Tumors</p><p>I. Invasive Urothelial Carcinomas</p><p>II. Flat Carcinoma In Situ (IUN III): Clinical Presentation, Histology</p><p></p><p>Histologic Variants of Urothelial Carcinoma</p><p>Metastatic Tumors </p><p>Cytologic Monitoring of Patients Treated for Tumors of Lower Urinary Tract</p><p>Reporting of cytologic findings</p><p>Suggested Reading</p><p>Chapter 7- Immunohistochemistry, Immunocytochemistry and Other Methods of Detection of Bladder Neoplasms</p><p>Introduction</p><p>US FDA-approved Markers</p><p>Potential Markers in Earlier Phases of Clinical Development</p><p>Markers Detected by Immunocytochemistry</p><p>Comparison between Urine Cytology and FDA-approved Markers</p><p>Conclusion</p><p>References</p>